Program – 2024

The 2024 Workshop Program is under development.
Program is subject to change. 

FRIDAY , JULY 26

Workshop Pretest available, to be completed by 1 p.m. on Sunday, July 28

SUNDAY, JULY 28

Registration
1:30 pm-5:30 pm

Faculty Meeting
4:30 pm-5:15 pm

Welcome/Overview
5:30 pm-5:45 pm
Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York
Wendy B. London, Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, Massachusetts
Julie M. Vose, University of Nebraska Medical Center, Omaha, Nebraska

Opening Keynote Lecture
Session Chair: Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York
5:45 pm-6:30 pm

  • Career Development Opportunities: The Government Can Help
    Oliver Bogler, National Cancer Institute, Rockville, Maryland

Dinner/Protocol Development Group Session 1
6:30 pm-8:30 pm

MONDAY, JULY 29

Breakfast
7:00 am-8:00 am

Lecture Session 1
8:00 am-9:45 am

  • Answering Important Questions: From Hypothesis to Analysis
    Wendy B. London, Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, Massachusetts
  • Phase I Trial Questions
    Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York
  • Phase I Trial Designs
    Shing Lee, Columbia University, New York, New York

Questions / Panel Discussion

Break
9:45 am-10:00 am

Lecture Session 2
10:00 am-12:00 pm

  • Phase II Trial Questions/Objectives
    Maha Hussain, Northwestern University Feinberg School of Medicine, Chicago, Ilinois
  • Phase II Trial Designs
    Sean Devlin, Memorial Sloan Kettering Cancer Center, New York, New York
  • Drug Combination Trials
    George A. Fisher, Jr., Stanford Cancer Institute, Stanford, California
  • Multimodality Trials
    Adam P. Dicker, Thomas Jefferson University, Philadelphia, Pennsylvania

Questions / Panel Discussion

Lunch
12:00 pm-1:30 pm

Protocol Development Group Session 2
1:30 pm-4:00 pm

Independent Study Time
4:00 pm-7:00 pm

Personalized Mentoring Session 1 (Biostatisticians and Patient Advocates; prescheduled appointments)
4:15 pm-6:30 pm

ASSIGNMENT DUE: PROTOCOL TEMPLATE
7:00 pm

Dinner
7:00 pm-9:00 pm

TUESDAY, JULY 30

Breakfast
7 am-8 am

Lecture Session 3
8:00 am-9:40 am

  • Feasibility and Reproducibility in Biomarker Studies
    Kurt A. Schalper, Yale University, New Haven, Connecticut
  • Incorporation of Biological Correlative Studies into Early Clinical Trials
    Jordi Rodon Ahnert, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Statistical Aspects of Correlative Studies
    James R. Anderson, University of Nebraska Medical Center, Omaha, Nebraska

Questions / Panel Discussion

Break
9:40 am-10:00 am

Lecture Session 4
10:00 am-11:40 am

  • Imaging in the Era of Targeted Therapy and Immunotherapy
    Ammar Chaudhry, AstraZeneca, Yorba Linda, California
  • Special Considerations in the Design of Immunotherapy Studies
    Amir A. Jazaeri, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Barriers to Accrual and How to Overcome Them
    Ruth O’Regan, University of Rochester, Rochester, New York

Questions / Panel Discussion

Lunch
11:40 am-12:45 pm

Protocol Development Group Session 3
12:45 pm-3:45 pm

Independent Study Time
3:45 pm-7:00 pm

Personalized Mentoring Session 2: Protocol Related Questions
3:45 pm-6:00 pm
Room locations noted on signup sheets
(Signup sheets will be available during the morning break.)

Dinner (Grab and Go)
5:00 pm-7:00 pm

ASSIGNMENT DUE: STATISTICAL DESIGN
7:00 pm

WEDNESDAY, JULY 31

Breakfast
7:00 am-8:00 am

Small Group Discussion Sessions 1-3
8:00 am-9:00 am

  • Elements of Artificial Intelligence
    Carole Baas, NCI Physical Sciences in Oncology Network, Southlake, Texas
    Ammar Chaudhry, AstraZeneca, Yorba Linda, California
    Neal J. Meropol, Flatiron Health, New York, New York
    John Rice, University of Michigan, Ann Arbor, Michigan
  • Symptom Management, Patient Reported Outcomes, and Quality of Life
    Vijaya R. Bhatt, University of Nebraska Medical Center, Omaha, Nebraska
    Jill Feldman, EGFR Resisters, Evanston, Illinois
    Sujata Patil, Cleveland Clinic, Cleveland, Ohio
  • Phase III Trials
    Maura N. Dickler, Genentech, South San Francisco, California
    Josh Mailman, NorCal CarciNET Community, Oakland, California
    Lindsay Renfro, University of Southern California, Los Angeles, California

Break
9:00 am-9:15 am

Small Group Discussion Sessions 4-6
9:15 am-10:15 am

  • Navigating the National Clinical Trials Network
    Vijaya R. Bhatt, University of Nebraska Medical Center, Omaha, Nebraska
    Colin Weekes, Massachusetts General Hospital, Boston, Massachusetts
  • Laboratory Correlates, ctDNA, and Liquid Biopsy
    Emily V. Dressler, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    Ruth O’Regan, University of Rochester, Rochester, New York
    Kurt A. Schalper, Yale University, New Haven, Connecticut

Break / Group Photo
10:15 am-10:45 am

Small Group Discussion Sessions 7-9
10:45 am-11:45 am

  • Defining, Identifying, and Knowing Your Trial’s Clinical Endpoints
    John Byrd, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Chen Hu, Johns Hopkins University, Baltimore, Maryland
    Sanford Jeames, PCORI/Huston-Tillotson University, Austin, Texas
  • Understanding the Regulatory Process
    Jordi Rodon Ahnert, The University of Texas MD Anderson Cancer Center, Houston, Texas
    James R. Anderson, University of Nebraska Medical Center, Omaha, Nebraska
    Neal J. Meropol, Flatiron Health, New York, New York
    Franklin Smith, Medpace, Cincinnati, Ohio
  • Large-Scale Genomic Analysis: Bench to Bedside
    Manju George, Colontown, Crowdsville, Maryland
    David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York

Lunch
11:45 am-12:30 pm

Protocol Development Group Session 4
12:30 pm-2:30 pm

Independent Study Time/Dinner on Own
2:30 pm-7:00 pm

Personalized Mentoring Session 3: Protocol Related Questions
3:45 pm-6:00 pm
Room locations noted on signup sheets
(Signup sheets will be available during the morning break.)

ASSIGNMENT DUE: PROTOCOL DRAFTS
7:00 pm

THURSDAY, AUGUST 1

Breakfast
7:00 am-8:00 am

Lecture Session 5
8:00 am-9:40 am

  • You’re in Charge: Investigator Responsibilities
    John P. Leonard, Weill Cornell Medicine, New York, New York
  • How to Pay for Your Trial
    Richard D. Carvajal, Northwell Health Cancer Institute, New York, New York
  • Everything You Need to Know About Clinical Trial Ethics and Informed Consent
    Diana T. Chingos, DTC Consulting, Los Angeles, California
    Laura C. Michaelis, Medical College of Wisconsin, Milwaukee, Wisconsin

Questions / Panel Discussion

Break
9:40 am-9:55 am

Lecture Session 6
9:55 am-11:35 am

  • Data Collection: It’s All In the Data
    Mark Krailo, Children’s Oncology Group, Los Angeles, California
  • Inclusivity in Clinical Trials
    Everett E. Dodson, Georgetown Lombardi Comprehensive Cancer Center (Retired), Washington DC
    Colin Weekes, Massachusetts General Hospital, Boston, Massachusetts
  • Community Engagement
    Sanford Jeames, PCORI/Huston-Tillotson University, Austin, Texas

Questions / Panel Discussion

Break
11:35 am-11:45 am

Keynote Lecture
11:45 am-12:35 pm

  • Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut

Lunch
12:35 pm-1:30 pm

Protocol Development Group Session 5
1:30 pm-3:00 pm

Independent Study Time/Dinner on Own
3:00 pm-7:00 pm

Personalized Mentoring Session 4: Informed Consent/Protocol Related Questions, and Career Guidance
3:15pm-5:30 pm
Room locations noted on signup sheets
(Signup sheets will be available during the morning breaks.)

Optional Networking Session: Women in Hematology/Oncology
5:30 pm-6:30 pm

ASSIGNMENT DUE: INFORMED CONSENT DOCUMENTS
7:00 pm

FRIDAY, AUGUST 2

Breakfast
7:00 am-8:30 am

Faculty Meeting (Faculty Only)
7:30 am-8:30 am

Optional Career Sessions
(Exact topics to be determined based on accepted applicant interests, topics shown below are examples from past Workshops)
8:30 am-9:30 am

  • Collaborating and Networking
    Maura N. Dickler, Genentech, South San Francisco, California
    Andrew M. Lowy, University of California, San Diego, California
    Neal J. Meropol, Flatiron Health, New York, New York
  • Work-Life Balance
    Jeff Bogart, State University of New York, Syracuse, New York
    Tari King, Dana-Farber Cancer Institute/Brigham and Women’s Cancer, Boston, Massachusetts
    Franklin O. Smith, Medpace, Cincinnati, Ohio
  • Career Transition and Advancement Tips
    David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York
    Julie M. Vose, University of Nebraska Medical Center, Omaha, Nebraska

Break
9:30 am-9:45 am

Lecture Session 7
9:45 am-11:15 am

  • Successful Grantsmanship
    Alex A. Adjei, Cleveland Clinic, Cleveland, Ohio
  • Reporting and Presenting Results
    Tari King, Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, Boston, Massachusetts
    Shing Lee, Columbia University, New York, New York
    Mary W. Redman, Fred Hutchinson Cancer Center, Seattle, Washington

Questions / Panel Discussion

Break
11:15 am-11:30 pm

Protocol Development Group Session 6
11:30 am-1:00 pm

Lunch (Boxed)
1:00 pm-2:00 pm

Administration of Post-test
1:00 pm-4:00 pm

Independent Study Time
1:00 pm-7:00 pm

ASSIGNMENT DUE: FINAL PROTOCOLS, INFORMED CONSENT FORMS, and ALL WORKSHOP EVALUATIONS
7:00 pm

Closing Reception / Banquet / Dance
7:00 pm-11:00 pm

SATURDAY, AUGUST 3

Departure (on own)